Beyond prostate, beyond surgery and beyond urology: The “3Bs” of managing non-neurogenic male lower urinary tract symptoms

doi:10.1016/j.ajur.2017.11.002

Asian Journal of Urology, 2019, 6 (2): 169-173 doi: 10.1016/j.ajur.2017.11.002

Perspective

Beyond prostate, beyond surgery and beyond urology: The “3Bs” of managing non-neurogenic male lower urinary tract symptoms

Qixiang Song^a,Paul Abrams^b,*(

),Yinghao Sun^a,*(

)

a. Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China;
b. Bristol Urological Institute, Southmead Hospital, Bristol, UK

Abstract
Related Citation (15)

Download:

HTML

PDF (2036KB)
Export: BibTeX | EndNote (RIS)

Abstract

Lower urinary tract symptoms (LUTS), consisting storage, voiding and post-micturition symptoms, is a comprehensive definition involving symptoms that may occur due to several causes. Instead of simply focusing on the enlarged prostate, more attention has to be paid to the entire urinary tract as well as multiple system comorbidities. Therefore, prostate surgery alone does not necessarily provide adequate management and cross-disciplinary collaborations are sometimes required. Based on current literature, this paper proposes the “3Bs” concept for managing non-neurogenic male LUTS, namely, “beyond prostate”, “beyond surgery” and “beyond urology”. The clinical application of the “3Bs” enables urologists to carry out integrated, individualized and precise medical care for each non-neurogenic male LUTS patient.

Key words： Male Lower urinary tract symptoms Benign prostatic hyperplasia Benign prostatic obstruction Detrusor overactivity Detrusor underactivity Prostate surgery Comorbidities

Received: 27 July 2017 Available online: 23 November 2017

Corresponding Authors: Paul Abrams,Yinghao Sun E-mail: paul.abrams@bui.ac.uk;sunyhsmmu@126.com

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Qixiang Song
	Paul Abrams
	Yinghao Sun

TRENDMD:

Cite this article:

Qixiang Song,Paul Abrams,Yinghao Sun. Beyond prostate, beyond surgery and beyond urology: The “3Bs” of managing non-neurogenic male lower urinary tract symptoms[J]. Asian Journal of Urology, 2019, 6(2): 169-173.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2017.11.002 OR http://www.ajurology.com/EN/Y2019/V6/I2/169

[1]	P. Abrams, L. Cardozo, M. Fall, D. Griffiths, P. Rosier, U. Ulmsten , et al.The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.Neurourol Urodyn, 21(2002), pp. 167-178.
[2]	P. Abrams.New words for old: lower urinary tract symptoms for “prostatism.BMJ, 308(1994), pp. 929-930. doi: 10.1136/bmj.308.6934.929
[3]	J. de la Rosette, G. Alivizatos, S. Madersbacher, C. Rioja Sanz, J. Nordling, M. Emberton , et al.Guidelines on benign prostatic hyperplasia.Guidelines on benign prostatic hyperplasia.( 2009).https://uroweb.org/wp-content/uploads/EAU-Guidelines-BPH-2009.pdf.
[4]	M. Oelke, A. Bachmann, A. Descazeaud, M. Emberton, S. Gravas, M.C. Michel , et al.Guidelines on the treatment of non-neurogenic male LUTS.Guidelines on the treatment of non-neurogenic male LUTS.(2011).https://uroweb.org/wp-content/uploads/12_Male_LUTS.pdf.
[5]	M. Oelke, A. Bachmann, A. Descazeaud, M. Emberton, S. Gravas, M.C. Michel, et al.Guidelines on management of non-neurogenic male lower urinary tract symptoms ( LUTS),incl. benign prostatic obstruction (BPO).(2013).http://uroweb.org/wp-content/uploads/EAU-Guidelines-Male_LUTS-2013.pdf .
[6]	S. Gravas, T. Bach, M. Drake, M. Gacci, C. Gratzke, T.R.W. Herrmann, et al.EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO).(2017).http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5 .
[7]	C.R. Chapple ,C.G. Roehrborn.A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder.Eur Urol, 49(2006), pp. 651-658. doi: 10.1016/j.eururo.2006.02.018 pmid: 16530611
[8]	C.G. RoehrbornBenign prostatic hyperplasia: an overview.Rev Urol,7(Suppl 9) ( 2005), pp. S3-S14. doi: 10.1016/S0090-4295(98)00532-9 pmid: 16985902
[9]	R. Soler, K.E. Andersson, M.B. Chancellor, C.R. Chapple , W.C. de Groat, M.J. Drake, et al.Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms.Eur Urol, 64(2013), pp. 610-621. doi: 10.1016/j.eururo.2013.04.042 pmid: 23711541
[10]	S.J. Berry, D.S. Coffey, P.C. Walsh ,L.L. Ewing.The development of human benign prostatic hyperplasia with age.J Urol, 132(1984), pp. 474-479. doi: 10.1111/j.1464-410X.1984.tb06161.x pmid: 6206240
[11]	M. Oelke, J. Baard, H. Wijkstra , J.J. de la Rosette, U. Jonas, K. Hofner.Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.Eur Urol, 54(2008), pp. 419-426. doi: 10.1016/j.eururo.2008.02.017 pmid: 18325657
[12]	M. Kang, M. Kim, M.S. Choo, J.S. Paick ,S.J. Oh.Urodynamic features and significant predictors of bladder outlet obstruction in patients with lower urinary tract symptoms/benign prostatic hyperplasia and small prostate volume.Urology, 89(2016), pp. 96-102. doi: 10.1016/j.urology.2015.11.027 pmid: 26683755
[13]	G.S. Gerber, E.R. Goldfischer, T.G. Karrison , G.T. Bales.Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.Urology, 49(1997), pp. 697-702. doi: 10.1016/S0090-4295(97)00069-1 pmid: 9145973
[14]	National Kidney FoudationK/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am J Kidney Dis, 39(2002), pp. S1-S266.
[15]	P.E. Stevens, A. Levin, Group KDIGOCKDGDW.Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med, 158(2013), pp. 825-830.
[16]	S.K. Hong, S.T. Lee, S.J. Jeong , S.-S. Byun, Y.K. Hong, D.S. Park, et al.Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia.BJU Int, 105(2010), pp. 1424-1428.
[17]	T. Yamasaki, T. Naganuma, T. Iguchi, Y. Kuroki, N. Kuwabara, Y. Takemoto , et al.Association between chronic kidney disease and small residual urine volumes in patients with benign prostatic hyperplasia.Nephrol Carlt, 16(2011), pp. 335-339. doi: 10.1111/j.1440-1797.2010.01430.x pmid: 21126286
[18]	J.J. Pariser, S.M. Pearce, S.G. Patel , G.T. Bales.National trends of simple prostatectomy for benign prostatic hyperplasia with an analysis of risk factors for adverse perioperative outcomes.Urology, 86(2015), pp. 721-725. doi: 10.1016/j.urology.2015.06.048 pmid: 26276574
[19]	J.P. Ingimarsson, H.J. Isaksson, H.P. Sigbjarnarson, J. Gudmundsson , G. Geirsson.Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.Scand J Urol, 48(2014), pp. 73-78. doi: 10.3109/21681805.2013.825878 pmid: 23924152
[20]	R. Vela-Navarrete, C. Gonzalez-Enguita, J.V. Garcia-Cardoso, F. Manzarbeitia, J.L. Sarasa-Corral , J.J. Granizo.The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade( 1992-2002). BJU Int, 96(2005), pp. 1045-1048. doi: 10.1111/j.1464-410X.2005.05735.x pmid: 16225526
[21]	C.T. Brown, T. Yap, D.A. Cromwell, L. Rixon, L. Steed, K. Mulligan , et al.Self management for men with lower urinary tract symptoms: randomised controlled trial.BMJ,334(2007), p. 25,http://doi.org/10.1136/bmj.39010.551319 .
[22]	A.W. Thomas, A. Cannon, E. Bartlett, J. Ellis-Jones , P. Abrams.The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up.BJU Int, 93(2004), pp. 745-750. doi: 10.1097/01.ju.0000168167.63454.e2 pmid: 15049984
[23]	F. Housami , P. Abrams.Persistent detrusor overactivity after transurethral resection of the prostate.Curr Urol Rep, 9(2008), pp. 284-290. doi: 10.1007/s11918-007-0018-3 pmid: 18765127
[24]	K.D. Sievert , T. Kunit.Emerging techniques in ‘truly’ minimal-invasive treatment options of benign prostatic obstruction.Curr Opin Urol, 27(2017), pp. 287-292. doi: 10.1097/MOU.0000000000000386 pmid: 28319477
[25]	M.S. Choo, J.H. Han, T.Y. Shin, K. Ko, W.K. Lee, S.T. Cho , et al.Alcohol, smoking, physical activity, protein, and lower urinary tract symptoms: prospective longitudinal cohort.Int Neurourol J, 19(2015), pp. 197-206.
[26]	M.S. Bolat, E. Akdeniz, S. Ozkaya, A.F. Batur, K.G. Kutman, R. Goren , et al.Smoking and lower urinary tract symptoms.Urol J, 12(2015), pp. 2447-2451.
[27]	M.A. Denys, R. Anding, A. Tubaro, P. Abrams, K. Everaert.Lower urinary tract symptoms and metabolic disorders: ICI-RS 2014. Neurourol Urodyn, 35(2016), pp. 278-282.
[28]	F. Hirayama, A.H. Lee, C.W. Binns, H. Taniguchi, K. Nishimura , K. Kato.Urinary incontinence in men with chronic obstructive pulmonary disease.Int J Urol, 15(2008), pp. 751-753.
[29]	Y.H. Peng, C.W. Huang, W.C. Liao, H.J. Chen, M.C. Yin, Y.M. Huang , et al.Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study.BMJ open, 7(2017), p. e015581,http://doi.org/10.1136/bmjopen-2016-015581 .
[30]	P. Van Kerrebroeck, K.E. Andersson. Terminology, epidemiology, etiology, pathophy siology of nocturia.Neurourol Urodyn, 1(33 Suppl)( 2014), pp. S2-S5
[31]	J.P. Weiss, J.L. Bosch, M. Drake, R.R. Dmochowski, H. Hashim, A. Hijaz , et al.Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol Urodyn, 31(2012), pp. 330-339.